Clinical trial
S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly…
NCT00006721 · SWOG Cancer Research Network, Other · Active, not recruiting
Key facts
| NCT number | NCT00006721 |
|---|---|
| Title | S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma |
| Official title | A Phase III Trial of CHOP Plus Rituximab vs CHOP Plus Iodine-131-Labeled Monoclonal Anti-B1 Antibody (Tositumomab) for Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphomas |
| Lead sponsor | SWOG Cancer Research Network, Other |
| Collaborators | National Cancer Institute (NCI) NIH Cancer and Leukemia Group B Eastern Cooperative Oncology Group |
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Drug, Radiation |
| Interventions | rituximab, cyclophosphamide, doxorubicin, prednisone, vincristine, tositumomab |
| Enrollment | 571 |
| Start date | Mar 1, 2001 |
| Primary completion | Sep 1, 2011 |
| Completion | Dec 1, 2025 |
| First posted | Jan 27, 2003 |
| Last update posted | May 21, 2025 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: